Table 2.
Patient Outcomes
| Outcome | Control (n=111) | Clinical Pharmacy-Managed | P-value (n=113) |
|---|---|---|---|
| Blood Pressure | |||
| BP Controlled (%) | 40.7 | 64.6 | 0.0021 |
| Mean Systolic mmHg Δ (SD) | -17.6 (21.0) | -28.4 (23.6) | 0.0481 |
| Mean Diastolic mmHg Δ (SD) | -6.6 (10.7) | -16.5 (11.9) | <0.0011 |
| Medication (%) | |||
| Thiazide Diuretic | 33.3 | 68.1 | <0.001 |
| Loop Diuretic | 5.4 | 2.7 | 0.295 |
| Beta Blocker | 36.0 | 47.8 | 0.075 |
| ACE Inhibitor | 37.8 | 37.2 | 0.918 |
| Alpha Blocker | 9.0 | 1.8 | 0.009 |
| Dihydropyridine Ca++ Blocker | 13.5 | 15.0 | 0.743 |
| Non-Dihydropyridine Ca++ Blocker | 18.0 | 22.1 | 0.443 |
| Central Acting Agent | 8.1 | 10.6 | 0.519 |
| Mean Count of BP-Related Office Visits (SD) | 1.8 (0.8) | 1.3 (1.0) | 0.020 |
| Mean Count of BP-Related Phone Calls (SD) | 0.2 (0.7) | 1.6 (2.2) | <0.001 |
| Home/Community BP Monitoring (%) | 1.8 | 54.5 | <0.001 |
1 - Adjusted for age, sex, pre-period systolic BP, pre-period diastolic BP, diabetes status, and alpha blocker use
ACE = angiotensin-converting enzyme, BP = blood pressure, Ca++ = calcium, Δ = change, SD = standard deviation